EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Disease burden in primary sclerosing cholangitis in the Netherlands: A long‐term follow‐up study

Kim N van Munster iD, Bregje Mol, Jorn C Goet, Sanne N van Munster, Rinse K Weersma, Annemarie C de Vries, Adriaan J van der Meer, Akin Inderson, Joost P Drenth iD, Karel J van Erpecum, Kirsten Boonstra, Ulrich Beuers iD und 3 weitere

Liver International · 2023-03 · 43 (3) · 639-648

DOI: 10.1111/liv.15471 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, online erschienen am 15.11.2022. Verfasst von Kim N van Munster und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Amsterdam University Medical Center, location AMC, Amsterdam Gastroenterology, Endocrinology & Metabol…. Hauptthemen laut MEDLINE: Cholangitis, Sclerosing. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ZonMw.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Aims Primary sclerosing cholangitis (PSC) is a progressive, cholestatic liver disease which greatly impacts the lives of individuals. Burden of disease due to shortened life expectancy and impaired quality of life is ill‐described. The aim of this study was to assess long‐term disease burden in a large population‐based registry with regard to survival, clinical course, quality adjusted life years (QALYs), medical consumption and work productivity loss.

Methods

All PSC patients living in a geographically defined area covering ~50% of the Netherlands were included, together with patients from the three liver transplant centres. Survival was estimated by competing risk analysis. Proportional shortfall of QALYs during disease course was measured relative to a matched reference cohort using validated questionnaires. Work productivity loss and medical consumption were evaluated over time.

Results

A total of 1208 patients were included with a median follow‐up of 11.2 year. Median liver transplant‐free survival was 21.0 years. Proportional shortfall of QALYs increased to 48% >25 years after diagnosis. Patients had on average 12.4 hospital contact days among which 3.17 admission days per year, annual medical costs were €12 169 and mean work productivity loss was 25%.

Conclusions

Our data quantify for the first time disease burden in terms of QALYs lost, clinical events, medical consumption, costs as well as work productivity loss, and show that all these are substantial and increase over time.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cholangitis, SclerosingHumansFollow-Up StudiesQuality of LifeNetherlandsCost of Illness

Stichwörter der Autor:innen

PSCQALYdisease burdenmedical costssurvivalwork productivity loss

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Amsterdam University Medical Center, location AMC, Amsterdam Gastroenterology, Endocrinology & Metabolism, Amsterdam, The Netherlands.
  • Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
  • Department of Gastroenterology and Hepatology, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands.
  • Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands.

ORCID-Profile: Kim N van Munster, Joost P Drenth, Ulrich Beuers, Cyriel Y Ponsioen

Förderung

  • ZonMw

Zitieren

APA

van Munster, K. N., Mol, B., Goet, J. C., van Munster, S. N., Weersma, R. K., de Vries, A. C., van der Meer, A. J., Inderson, A., Drenth, J. P., van Erpecum, K. J., Boonstra, K., Beuers, U., Dijkgraaf, M. G. W., Ponsioen, C. Y., & EpiPSC2 Study Group (2023). Disease burden in primary sclerosing cholangitis in the Netherlands: A long‐term follow‐up study. Liver International, 43(3), 639-648. https://doi.org/10.1111/liv.15471

Vancouver

van Munster KN, Mol B, Goet JC, van Munster SN, Weersma RK, de Vries AC, et al. Disease burden in primary sclerosing cholangitis in the Netherlands: A long‐term follow‐up study. Liver International. 2023;43(3):639-648. doi:10.1111/liv.15471

BibTeX
@article{vanMunster2023,
  author = {van Munster, Kim N and Mol, Bregje and Goet, Jorn C and van Munster, Sanne N and Weersma, Rinse K and de Vries, Annemarie C and van der Meer, Adriaan J and Inderson, Akin and Drenth, Joost P and van Erpecum, Karel J and Boonstra, Kirsten and Beuers, Ulrich and Dijkgraaf, Marcel G W and Ponsioen, Cyriel Y and EpiPSC2 Study Group, EpiPSC2 Study Group},
  title = {Disease burden in primary sclerosing cholangitis in the Netherlands: A long‐term follow‐up study},
  journal = {Liver International},
  year = {2023},
  volume = {43},
  number = {3},
  pages = {639--648},
  doi = {10.1111/liv.15471}
}
Kostenlos starten →